Immunotherapy — particularly checkpoint inhibitors like pembrolizumab (Keytruda), nivolumab (Opdivo), ipilimumab (Yervoy), and atezolizumab (Tecentriq) — has transformed cancer treatment across dozens of tumor types. It also comes with a nutrition conversation that's different from what most people expect.
Patients on immunotherapy often feel relatively well compared to patients on traditional chemotherapy. There's no hair loss, often less nausea, and many people can eat relatively normally — at least initially. This leads to a common misconception: that nutrition doesn't matter as much on immunotherapy. In some ways the opposite is true. The gut microbiome, body composition, inflammatory status, and specific dietary factors all have emerging evidence for influencing how well immunotherapy works — not just how well you tolerate it.
This post covers what we know, what's still evolving, and what's practical.
How Immunotherapy Is Different From Chemotherapy
To understand the nutrition implications, it helps to understand the mechanism. Checkpoint inhibitors work by releasing the "brakes" on the immune system — specifically by blocking PD-1, PD-L1, or CTLA-4 checkpoint proteins that tumors exploit to hide from immune surveillance. The result is a reinvigorated immune response against the tumor.
The tradeoff: that same reinvigorated immune system can attack healthy tissues, producing what are called immune-related adverse events (irAEs). Unlike chemotherapy toxicity, which is largely predictable and tied to cell division rate, irAEs are immune-mediated, highly variable in timing and organ involvement, and sometimes severe.
| Feature | Chemotherapy | Checkpoint Inhibitors |
|---|---|---|
| Mechanism of toxicity | Direct cytotoxicity — damages rapidly dividing cells including GI mucosa, bone marrow, hair follicles | Immune-mediated — overactivated immune system attacks healthy tissue |
| GI side effects | Nausea, vomiting, mucositis, diarrhea from mucosal damage | Immune-mediated colitis (diarrhea), less nausea/vomiting overall |
| Timing of side effects | Predictable — tied to infusion cycle, nadir | Unpredictable — can occur weeks to months after starting or even after stopping |
| Nutritional impact (typical) | Significant: nausea, taste changes, mucositis, appetite suppression | Often milder overall, but irAEs can be severe and nutritionally disruptive |
| Treatment for toxicity | Antiemetics, growth factors, dose modification | Corticosteroids, immunosuppressants — which have their own nutrition implications |
Immune-Related Adverse Events With Nutritional Implications
irAEs can affect virtually any organ system. The ones with direct nutrition implications include:
Immune-Mediated Colitis
The most nutritionally significant GI irAE. Presents as frequent, watery diarrhea — sometimes bloody — often with cramping. Can range from mild to life-threatening. Nutritional management depends on severity: mild cases may be managed with a low-residue diet and hydration; moderate to severe require corticosteroids and often temporary diet modification. Prolonged colitis can cause significant protein-calorie malnutrition.
Immune-Mediated Hepatitis
Elevated liver enzymes from immune-mediated liver inflammation. Nutritionally, this affects fat metabolism and liver-dependent nutrient processing. Alcohol should be eliminated entirely. Hepatotoxic supplements (kava, high-dose vitamin A, certain herbal compounds) must be avoided. A standard well-balanced diet is appropriate; there is no evidence that specific dietary changes improve hepatitis resolution.
Thyroid Dysfunction
Hypothyroidism and hyperthyroidism are among the most common irAEs with checkpoint inhibitors. Hypothyroidism slows metabolism, can worsen fatigue, and contributes to weight gain. Hyperthyroidism accelerates metabolism and can cause significant unintended weight loss. Both affect nutritional status and need monitoring — thyroid function should be checked regularly during treatment.
Immune-Mediated Pancreatitis
Less common but significant. Presents with elevated lipase/amylase and abdominal pain. Nutritional management follows standard pancreatitis principles: clear liquids to low-fat diet during acute phase, gradual reintroduction. Severe cases may require nutrition support. Fat restriction is the primary dietary modification.
Adrenal Insufficiency
Immune-mediated adrenal destruction (adrenalitis) can cause cortisol deficiency — presenting with fatigue, weight loss, nausea, and salt craving. Nutritional relevance: adequate sodium intake becomes important (unlike the general population recommendation to reduce sodium). This is managed with hormone replacement, not primarily through diet.
Type 1 Diabetes (irAE)
Checkpoint inhibitors can trigger fulminant type 1 diabetes through immune destruction of beta cells. This is rare but serious — can present as diabetic ketoacidosis. Requires immediate insulin management and ongoing carbohydrate-aware dietary counseling. Standard T1D nutrition principles apply.
New or worsening diarrhea, abdominal pain, yellowing of the skin or eyes, unusual fatigue, or any significant change in symptoms during immunotherapy should be reported to the oncology team promptly — not managed with dietary changes alone. Many irAEs require medical intervention and can worsen rapidly if untreated.
Managing Immune-Mediated Colitis: The Most Common GI irAE
Dietary Approach by Severity
- Grade 1 (mild): <4 stools above baseline per day. Low-residue, low-fiber diet to reduce bowel stimulation. Avoid raw vegetables, high-fiber grains, legumes, nuts, seeds, spicy foods, caffeine, alcohol, lactose (transient lactase deficiency is common with mucosal inflammation). Small, frequent meals. Maintain hydration aggressively.
- Grade 2 (moderate): 4–6 stools above baseline, significant cramping. Corticosteroids are typically initiated. Low-residue diet continues. Oral rehydration solutions to replace electrolytes. Protein intake becomes a priority — corticosteroids increase muscle protein catabolism. Monitor for nutritional deterioration.
- Grade 3–4 (severe): >7 stools above baseline, blood, severe cramping, fever. Hospitalization often required. May progress to bowel rest and parenteral nutrition. Dietitian involvement is essential at this stage. High-dose corticosteroids or infliximab are standard treatment; nutrition support is adjunctive.
- Hydration is non-negotiable at all grades. Oral rehydration solutions (not just water) replace the sodium, potassium, and glucose lost through diarrhea more effectively than plain fluid. Target urine that is pale yellow.
Foods to Favor During Colitis
- White rice, white bread, plain pasta, oatmeal (well-cooked)
- Bananas, applesauce, canned peaches or pears (peeled)
- Boiled or baked chicken or fish — plain, no heavy sauces
- Eggs — scrambled or boiled
- Broth-based soups with soft vegetables
- Boiled or steamed carrots, zucchini, peeled potatoes
- Lactose-free dairy or dairy alternatives if lactose is poorly tolerated
Corticosteroids for irAE Management: The Nutrition Implications
When irAEs require treatment with corticosteroids — prednisone, methylprednisolone, dexamethasone — the nutrition conversation shifts significantly. Steroids at therapeutic doses used for irAE management (often starting at 1–2 mg/kg/day prednisone equivalent) have major metabolic effects that require active nutritional management.
Nutritional Priorities During Corticosteroid Treatment for irAEs
- Increase protein intake to 1.5–2.0 g/kg/day. Corticosteroids directly stimulate muscle protein breakdown (gluconeogenesis) and impair muscle protein synthesis. Without adequate dietary protein, lean mass loss accelerates rapidly — even in patients who otherwise feel well.
- Manage blood glucose. Steroids cause significant insulin resistance and can precipitate steroid-induced hyperglycemia — even in patients with no prior diabetes history. Moderate carbohydrate intake, avoiding simple sugars and refined carbs, distributing carbohydrates across meals, and monitoring blood glucose are all appropriate. Patients on prolonged courses should have glucose checked regularly.
- Protect bone density. Corticosteroids reduce calcium absorption and accelerate bone loss. Calcium (1000–1200 mg/day from food and supplement) and vitamin D (maintain serum level ≥30 ng/mL) are important during any extended steroid course. Bisphosphonate therapy may be warranted for prolonged courses — an oncology or endocrinology decision.
- Sodium and fluid management. Steroids cause sodium retention and fluid accumulation. Reducing high-sodium processed foods is reasonable; dramatic sodium restriction is not typically necessary unless there is concurrent cardiovascular or renal disease.
- Potassium. Steroids promote potassium excretion. High-potassium foods (bananas, potatoes, avocado, leafy greens, legumes) are appropriate to emphasize if GI tolerance allows.
- Appetite increase. Corticosteroids stimulate appetite, sometimes dramatically. This is helpful when the underlying irAE has compromised intake — but in patients who are already eating adequately, it can drive significant and unwanted weight gain. Awareness and structured eating (not responding to every steroid-driven hunger cue) is appropriate.
The Microbiome Question: Can Diet Influence Immunotherapy Response?
This is the most rapidly evolving area in immunotherapy nutrition research — and one of the most clinically important questions being asked in oncology right now.
Multiple studies have shown that gut microbiome composition at the time of starting immunotherapy is associated with treatment response and survival outcomes. Patients with a more diverse microbiome, and specifically those with higher abundance of certain bacterial species (particularly Faecalibacterium prausnitzii, Akkermansia muciniphila, and Ruminococcaceae family members), tend to have better responses to checkpoint inhibitor therapy.
This has significant implications for diet, because gut microbiome composition is substantially shaped by what you eat:
- Dietary fiber is the primary fuel for beneficial gut bacteria. High-fiber diets consistently support microbial diversity. A study published in Science (2021) found that high dietary fiber intake was associated with improved progression-free survival on checkpoint inhibitor therapy, and that commercial probiotic use was associated with worse outcomes — potentially by homogenizing the microbiome.
- Plant diversity matters as much as plant quantity. Eating 30+ different plant foods per week — vegetables, fruits, whole grains, legumes, nuts, seeds, herbs — is associated with significantly higher microbiome diversity than eating fewer varieties, even at comparable total fiber intake. Variety, not just volume.
- Fermented foods support microbial diversity. A Stanford RCT (Wastyk et al., 2021) found that high fermented food intake increased microbiome diversity and reduced markers of systemic inflammation — both of which are relevant in the immunotherapy context. Yogurt, kefir, kimchi, sauerkraut, miso, and kombucha are all relevant sources.
- Processed food and high-fat Western dietary patterns reduce diversity and are associated with lower abundance of the bacterial species linked to immunotherapy response.
The microbiome-immunotherapy connection is real and biologically compelling — but the data is primarily associational. We do not yet have randomized trial evidence that deliberately modifying the gut microbiome through diet improves immunotherapy outcomes. The research is moving fast, and the dietary recommendations that follow from it (high fiber, high plant diversity, fermented foods) are low-risk and consistent with general health evidence regardless. But don't let anyone sell you a microbiome protocol that promises to make your immunotherapy work better — that's ahead of the evidence.
Probiotics During Immunotherapy: Use With Caution
The observational finding that commercial probiotic use was associated with worse immunotherapy outcomes (Gopalakrishnan et al., MD Anderson 2018) has not been definitively replicated, but it raised enough concern to change the conversation. The hypothesis is that introducing a small number of dominant bacterial strains through concentrated probiotic supplements may reduce native microbiome diversity — the opposite of what you want.
Current position from most oncology nutrition bodies: commercial probiotic supplements should not be routinely recommended during checkpoint inhibitor therapy, and patients taking them should discuss this with their oncologist. Fermented food sources of beneficial bacteria (which deliver a broader array of organisms in lower concentrations) are a different discussion and are not subject to the same concern.
What to Eat During Immunotherapy: The Core Recommendations
General Dietary Priorities
- Maximize plant diversity. Aim for 30+ different plant foods per week. This sounds like a lot but includes everything — different vegetables, fruits, whole grains, legumes, nuts, seeds, herbs, and spices. A diverse plant-forward diet is the single most evidence-supported dietary strategy for microbiome health during immunotherapy.
- High fiber — 25–38g/day. Prioritize whole food fiber sources: vegetables, legumes, whole grains, fruits with skin. Fiber supplements are not equivalent and don't deliver the associated phytonutrients and fermentable substrates.
- Include fermented foods regularly. Yogurt, kefir, kimchi, sauerkraut, miso, tempeh, kombucha. At least one serving daily if GI tolerance allows. Check tolerance — if colitis is active, fermented foods may need to be temporarily reduced.
- Adequate protein — 1.2–1.5 g/kg/day. Immunotherapy itself has relatively modest direct impact on protein status, but irAE management (particularly with corticosteroids) significantly increases protein needs. Maintain adequate intake throughout treatment.
- Anti-inflammatory dietary pattern overall. Olive oil, fatty fish, nuts, seeds, colorful vegetables and fruits, minimal processed food and refined carbohydrates. This aligns with both microbiome support and reduction of background systemic inflammation.
- Stay well hydrated. Especially important if diarrhea is present. Adequate hydration also supports kidney function, which handles clearance of immune complexes formed during treatment.
Supplements and Immunotherapy: What to Watch
The supplement interaction landscape during immunotherapy is less well-characterized than with chemotherapy, but several considerations are clinically important:
- High-dose antioxidant supplements are theoretically problematic. Immunotherapy works by stimulating immune-mediated tumor killing — a process that involves oxidative mechanisms. High-dose antioxidants (vitamin C >1g/day, vitamin E >400 IU/day, selenium) could theoretically blunt this. The evidence is not definitive, but the risk-benefit ratio does not favor routine high-dose antioxidant supplementation during active immunotherapy.
- Vitamin D supplementation is appropriate at standard doses to correct deficiency. Vitamin D has immunomodulatory properties, and emerging data suggest adequate vitamin D status may be associated with better immunotherapy outcomes.
- Herbal supplements with immune-stimulating properties (echinacea, astragalus, medicinal mushroom extracts at high doses) theoretically could amplify irAEs by further stimulating an already over-activated immune system. No definitive evidence, but caution is warranted and oncologist disclosure is essential.
- Omega-3 fatty acids at standard supplement doses (1–3g EPA+DHA/day) are anti-inflammatory and supported by general evidence. No specific safety concerns in immunotherapy.
- All supplements should be disclosed to the oncology team — the drug-supplement interaction database for immunotherapy is less developed than for chemotherapy, but that doesn't mean interactions don't exist.
Symptoms That Need Prompt Medical Attention During Immunotherapy
- Diarrhea with more than 4 loose stools per day above your normal baseline
- Any blood in stool
- Severe abdominal cramping or pain
- Yellowing of skin or eyes, dark urine, right upper quadrant pain (hepatitis signs)
- Significant unintended weight loss (>5% in a month)
- Extreme fatigue, dizziness, or salt craving (potential adrenal insufficiency)
- Excessive thirst or urination (potential immunotherapy-related diabetes)
- Any new symptom that seems unusual — irAEs can affect any organ and present atypically
Bottom Line
- Immunotherapy has a different toxicity profile than chemotherapy — nutrition management during treatment is less about managing nausea and more about supporting immune function, gut microbiome health, and irAE management.
- A high-fiber, plant-diverse, fermented food-inclusive diet has the strongest emerging evidence for supporting gut microbiome composition during checkpoint inhibitor therapy — and microbiome diversity is associated with better treatment response.
- Commercial probiotic supplements should not be used routinely during immunotherapy without oncologist discussion. Fermented foods are a different matter.
- Immune-mediated colitis is the most nutritionally disruptive irAE — management depends on severity and often involves corticosteroids, which significantly increase protein needs and require glucose and bone density monitoring.
- Thyroid dysfunction is a common irAE that can cause significant weight changes in either direction — hypothyroidism causes gain, hyperthyroidism causes loss. Both affect nutritional status.
- High-dose antioxidant supplements and immune-stimulating herbal supplements should be avoided or discussed with the oncology team during active immunotherapy.
- Nutrition during immunotherapy matters more than most patients are told — starting treatment with good nutritional status, maintaining it throughout, and managing irAE-related nutritional disruptions promptly all affect how well treatment goes.
On immunotherapy and unsure how to eat?
The nutrition picture during checkpoint inhibitor therapy is more nuanced than most people realize — and more impactful. A personalized plan can help you support your treatment and manage side effects before they escalate.
Book a Nutrition Consult